Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals and Lung Disease Patients
NCT03535545Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2018
- Primary completion
- Jun 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Gallium Ga 68 NODAGA-CBP8 in pulmonary fibrosis (PF), lung cancer, chronic lung allograft dysfunction (CLAD) and 1 more (5 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Ability to detect increased collagen deposition in pulmonary fibrosis at 2 hours. Started Aug 2018; status: recruiting.
02
Drugs
Gallium Ga 68 NODAGA-CBP8
03
Conditions
pulmonary fibrosis (PF)lung cancerchronic lung allograft dysfunction (CLAD)pneumonitis
Beyond the preview
Go deeper on NCT03535545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03535545.